Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|---|---|
Income Statement | ||||||
Total Revenue | 774.00M | 739.02M | 563.95M | 449.54M | 373.65M | 286.73M |
Gross Profit | 474.77M | 449.22M | 336.90M | 293.21M | 250.74M | 194.19M |
EBITDA | -397.86M | -390.12M | -433.31M | -614.91M | -359.62M | -225.07M |
Net Income | -416.55M | -436.37M | -479.45M | -654.59M | -384.77M | -246.28M |
Balance Sheet | ||||||
Total Assets | 1.34B | 1.49B | 1.79B | 1.61B | 2.20B | 2.27B |
Cash, Cash Equivalents and Short-Term Investments | 698.57M | 839.98M | 1.17B | 1.01B | 932.75M | 1.79B |
Total Debt | 1.31B | 1.34B | 1.35B | 1.37B | 1.36B | 847.86M |
Total Liabilities | 1.60B | 1.63B | 1.63B | 1.55B | 1.56B | 916.19M |
Stockholders Equity | -250.79M | -139.65M | 158.68M | 60.18M | 645.00M | 1.30B |
Cash Flow | ||||||
Free Cash Flow | -304.87M | -274.94M | -345.46M | -386.92M | -284.05M | -157.99M |
Operating Cash Flow | -272.26M | -239.86M | -324.98M | -309.46M | -209.02M | -103.93M |
Investing Cash Flow | 13.49M | -261.31M | 840.25M | 149.82M | -63.16M | -617.09M |
Financing Cash Flow | -66.77M | -996.00K | 477.38M | -189.09M | -66.82M | 1.41B |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
73 Outperform | $22.06B | ― | -18.66% | ― | 51.50% | 53.23% | |
72 Outperform | $9.37B | 24.88 | 65.82% | ― | 9.87% | 32.81% | |
61 Neutral | $3.30B | 134.41 | 5.88% | ― | 2.78% | -54.72% | |
57 Neutral | $6.22B | ― | -4584.47% | ― | 28.20% | 13.87% | |
54 Neutral | $10.30B | ― | -36.89% | ― | 11.57% | -315.25% | |
51 Neutral | $7.50B | 0.32 | -61.87% | 2.27% | 17.10% | 1.59% | |
51 Neutral | $10.25B | ― | -1252.79% | ― | 42.93% | -160.27% |
At the annual meeting of stockholders held on June 18, 2025, Guardant Health, Inc. elected all nominees for its board of directors, including Vijaya Gadde, Roberto Mignone, Myrtle Potter, and Musa Tariq. Additionally, the stockholders approved the selection of Deloitte & Touche LLP as the independent registered public accounting firm for 2025 and endorsed the compensation of the company’s named executive officers.
The most recent analyst rating on (GH) stock is a Buy with a $37.00 price target. To see the full list of analyst forecasts on Guardant Health stock, see the GH Stock Forecast page.